NCT03058211

Brief Summary

Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery (pneumolysin) or different biomarkers (histones, NETs(neutrophil extracellular traps), IL (Interleukin)-1b,h-Fabp (heart-Fatty acid bindding protein) ).The CVE frequency and its impact on outcome in patients without prior heart disease (CP) has not been studied. Objectives:1) To determine the incidence of myocardian injury (MI) and CVE in patients with CAP without CP evaluated by non-invasive techniques (Echocardiograph and MRI) and biomarkers levels (Tn-I (Troponin I), h-Fabp, NT-proBNP (N-terminal pro-brain natriuretic peptide) histones, NETs, IL 1b); 2) To assess if DMA and CVE are related to the etiology and their impact on outcome , 3) To investigate the presence of myocardial scarring by MRI and its relationship with etiology and MI, and 4) To identify prognostic factors of DMA and CVE to determine level of risk.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2018

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 10, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 20, 2017

Completed
1 year until next milestone

Study Start

First participant enrolled

March 1, 2018

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

July 1, 2021

Status Verified

June 1, 2021

Enrollment Period

1.2 years

First QC Date

February 10, 2017

Last Update Submit

June 29, 2021

Conditions

Keywords

Pneumococcal pneumoniaAcute cardiovascular events

Outcome Measures

Primary Outcomes (2)

  • Myocardian injury (scarring) in patients with CAP without cardiac disease (CP)history at 6 months of ICU admission

    MRI with late gadolinium increase and t1 mapping techniques for to detect myocardial scarring

    at 6 months

  • Heart dysfunction in patients with CAP without cardiac disease (CP)history in the first week of ICU admission

    Echocardiography with standard and strain techniques for to detect the presence of decrease in ejection fraction of both vetricules

    at day 7 of ICU admission)

Secondary Outcomes (3)

  • Temporal profile of the Troponin I as a cardiac injury biomarker in patients with CAP without cardiac disease (CP)history in the first week of ICU admission

    once per day ( days 1 to 7 of ICU admission)

  • Temporal profile of the N-terminal pro-brain natriuretic peptide(NT-proBNP) as a cardiac injury biomarker in patients with CAP without cardiac disease (CP)history in the first week of ICU admission

    once per day (days 1 to 7 of ICU admission)

  • Temporal profile of the heart- fatty acid binding protein (h-Fabp) as a cardiac injury biomarker in patients with CAP without cardiac disease (CP)history in the first week of ICU admission

    once per day (days 1 to 7 of ICU admission)

Study Arms (2)

pneumococcal pneumonia

Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.

Diagnostic Test: EchocardiographyDiagnostic Test: Cardiac Magnetic resonance

non-pneumococcal pneumonia

Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.

Diagnostic Test: EchocardiographyDiagnostic Test: Cardiac Magnetic resonance

Interventions

EchocardiographyDIAGNOSTIC_TEST

Standard protocols

Also known as: Heart resonance magnetic nuclear
non-pneumococcal pneumoniapneumococcal pneumonia

MRI with late gadolinium increase and T1 mapping

Also known as: MRI
non-pneumococcal pneumoniapneumococcal pneumonia

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Critically ill patients admitted to the intensive care unit due to severe community-acquired pneumonia

You may qualify if:

  • \- Patients admitted to the ICU due to community-acquired pneumonia according to IDSA/ATS criteria
  • \- No history of heart diasese
  • \- Informed consent signed

You may not qualify if:

  • \- Hospital or ventilator-associated pneumonia
  • \- Health care-associated pneumonia
  • \- Viral pneumonia
  • \- Bacterial/viral coinfection pneumonia
  • \- History of heart disease
  • \- Chronic administration of statins
  • \- Chronic administration of steorids (Prednisolone more 20 mg/day or equivalent)
  • \- No signed informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Critical Care Department - Hospital Universitario de Tarragona Joan XXIII

Tarragona, 43007, Spain

Location

Related Publications (4)

  • Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet. 2013 Feb 9;381(9865):496-505. doi: 10.1016/S0140-6736(12)61266-5. Epub 2013 Jan 16.

    PMID: 23332146BACKGROUND
  • Alhamdi Y, Neill DR, Abrams ST, Malak HA, Yahya R, Barrett-Jolley R, Wang G, Kadioglu A, Toh CH. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection. PLoS Pathog. 2015 May 14;11(5):e1004836. doi: 10.1371/journal.ppat.1004836. eCollection 2015 May.

    PMID: 25973949BACKGROUND
  • Brown AO, Mann B, Gao G, Hankins JS, Humann J, Giardina J, Faverio P, Restrepo MI, Halade GV, Mortensen EM, Lindsey ML, Hanes M, Happel KI, Nelson S, Bagby GJ, Lorent JA, Cardinal P, Granados R, Esteban A, LeSaux CJ, Tuomanen EI, Orihuela CJ. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014 Sep 18;10(9):e1004383. doi: 10.1371/journal.ppat.1004383. eCollection 2014 Sep.

    PMID: 25232870BACKGROUND
  • Lee YJ, Lee H, Park JS, Kim SJ, Cho YJ, Yoon HI, Lee JH, Lee CT, Park JS. Cardiac troponin I as a prognostic factor in critically ill pneumonia patients in the absence of acute coronary syndrome. J Crit Care. 2015 Apr;30(2):390-4. doi: 10.1016/j.jcrc.2014.12.001. Epub 2014 Dec 4.

    PMID: 25534985BACKGROUND

MeSH Terms

Conditions

Pneumonia, PneumococcalMyocardial Ischemia

Interventions

Echocardiography

Condition Hierarchy (Ancestors)

Pneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsPneumonia, BacterialPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract DiseasesHeart DiseasesCardiovascular DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

Cardiac Imaging TechniquesDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisUltrasonographyHeart Function TestsDiagnostic Techniques, Cardiovascular

Study Officials

  • Alejandro H Rodriguez Oviedo

    Hospital Universitari de Tarragona Joan XXIII

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD,PhD

Study Record Dates

First Submitted

February 10, 2017

First Posted

February 20, 2017

Study Start

March 1, 2018

Primary Completion

May 31, 2019

Study Completion

December 31, 2019

Last Updated

July 1, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Available IPD Datasets

Study Protocol (PI16/00486)Access
Informed Consent Form (PI16/00486)Access

Locations